The HORIZONS-AMI trial showed that bivalirudin therapy significantly reduces major bleeding and cardiac death in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending (LAD) artery. In high-risk STEMI patients, bivalirudin also provides the greatest mortality benefit.
The TCT 2009 symposium will feature a discussion on Electronic Health Records (EHR) and Personal Health Records (PHR), considering selection, implementation, and economics of these solutions. National experts will also address the implications of ARRA and healthcare reform on EHR.
A meta-analysis of 190,000 patients from 56 studies found no overall differences in death and myocardial infarction between drug-eluting stents (DES) and bare metal stents (BMS), with significant reductions in target vessel revascularization procedures.
A landmark study published in the New England Journal of Medicine found that paclitaxel-eluting stents reduce target lesion revascularization rates and binary angiographic restenosis compared to bare-metal stents. The study also showed comparable safety profiles for both types of stents.
A new study found a low number of strokes and cardiac events in patients treated with the FiberNet Embolic Protection System during carotid stenting. The system's unique filter design and ease of use contributed to these low event rates.
A study published at the TCT scientific symposium found that a novel blood flow reversal system used during carotid stenting is safe and effective, with a low death rate of 0.8% and major adverse event rate of 3.7%. The system offers potential advantages over existing devices by directing embolic particles away from the brain.
The HORIZONS AMI trial found that bivalirudin significantly reduces all-cause death, cardiac death, and major bleeding in heart attack patients. The use of bivalirudin also resulted in a 31% reduction in 1-year all cause mortality.
A clinical trial showed that drug-eluting stents are more effective than bare metal stents in reducing target lesion revascularization rates by 41% and binary restenosis by 56%. The use of drug-eluting stents also demonstrated comparable safety, with a reduced risk of major adverse cardiovascular events.
The SYNTAX trial found comparable safety and efficacy rates between drug-eluting stents and heart bypass surgery in patients with left main disease. Stent use resulted in fewer strokes, while bypass surgery had higher revascularization rates.
A clinical trial on therapeutic endovascular cooling found that the treatment is well-tolerated and can be safely achieved in high-risk patients. The study, presented at TCT 2008, used a novel approach to cool patients' kidneys before administering contrast agents during cardiac catheterization procedures.
Research studies and clinical registry data suggest that triple antiplatelet therapy achieves greater platelet inhibition than conventional dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents. This leads to reduced early mortality and major adverse cardiac events without in...
Researchers have found that optical coherence tomography (OCT) is the best tool available to detect vulnerable plaque, a possible cause of sudden cardiac death. OCT provides superior contrast and resolution in imaging the components of plaque, allowing for better understanding of coronary artery disease progression.
Research found that coronary heart disease symptoms presented in the context of stress were identified as psychogenic in origin when presented by women and organic in origin when presented by men. This study sheds light on why there is often a delay in diagnosing CHD in women, highlighting a gender bias in diagnosis and treatment.
A recent study suggests that olmesartan, a commonly used high blood pressure medication, can help reduce plaque in the coronary arteries of patients with stable angina. The trial involved 247 patients who received either 20-40mg/day of olmesartan or control, and showed significant decreases in plaque volume after 14 months of treatment.
Three new devices are being showcased to reduce blockages in peripheral and coronary arteries, providing cardiac support. The AngioSculpt device optimizes stenting of complex lesions with a low rate of complications.
The HORIZONS AMI trial found bivalirudin significantly reduces major bleeding and cardiovascular events in STEMI patients undergoing angioplasty. The study showed a 24% reduction in net adverse clinical events and a 33% decrease in overall mortality at 30 days.
The study analyzed 180,000 patients from 52 studies, demonstrating small non-significant reductions in death and myocardial infarction with a greater than 50% decrease in subsequent TVR procedures. Significant 20% and 11% reductions in death and MI were also observed, even after adjustment for confounding variables.
A study of over 13,000 patients found that bivalirudin alone and other regimens have comparable mortality and ischemic outcomes at 1 year. Bivalirudin monotherapy reduces bleeding complications and hospital costs, making it a favored treatment option
The HORIZONS AMI trial demonstrated the superiority of bivalirudin over standard drug therapy in reducing net adverse clinical events by 24% and major bleeding by 40% in heart attack patients at 30 days. The study showed significant reductions in cardiac deaths, with a 27% decrease compared to standard therapy.
The SPIRIT III trial found that the Xience V everolimus-eluting coronary stent significantly reduced major adverse cardiac events, including heart attacks and deaths from cardiac causes, by 50% after 12 months compared to the Taxus paclitaxel-eluting stent. This reduction in events is an important finding for patients with heart disease.
The AMIHOT II trial found that infusing oxygen-saturated blood into the previously blocked artery after an angioplasty procedure significantly reduced the size of the 'infarct zone', or damaged heart tissue. The study showed a 6.5% reduction in infarct zone size and no significant increase in Major Adverse Cardiac Events at 30 days.
Researchers present studies evaluating percutaneous procedures to repair and replace defective heart valves, demonstrating clinical improvements for high-risk patients. The devices have been shown to provide sustained symptom improvement for at least 6-12 months in these patients.
Research suggests that early intervention with angioplasty improves survival and reduces the risk of heart attack in women. Women are at higher risk of bleeding complications, but this does not justify withholding life-saving procedures.
The HORIZONS AMI trial enrolled over 3600 patients with a heart attack, examining the safety and effectiveness of stents and anticoagulants in heart attack patients undergoing angioplasty. The study aims to determine whether using bivalirudin provides the same benefit as standard anticoagulant therapy without causing excess bleeding.